Clinically validated solutions and platforms modernizing patient care.
Healthcare and biotech deals on OBC prioritize clinically or commercially validated models, avoiding pure pre-clinical scientific risk unless expressly disclosed.
Ticket size, term, exit mechanics and reporting are all shaped in the specialist conversation we have with you. What you see here is our default posture per sector — the final terms are tailored to your strategy call and the deal-qualification call before you commit.
The same 4 stages apply to every healthcare & biotech deal — with escrow release only after shares are transferred to investors.
Specialist advisors and healthcare operators.
Clinical, regulatory, reimbursement and IP review.
Tranches aligned with regulatory milestones.
Wire from escrow after documentation completes.
No investment is risk-free. These are the primary risk categories we assess for healthcare & biotech deals.